Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Startseite Know-how Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

The aim of this study was to confirm the efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) in reducing clinical respiratory signs and the number of concomitant treatments under field conditions.

Über diesen Artikel

Datum

06.09.2016

Zusammenfassung

Vaccination with the commercial vaccine HIPRABOVIS® SOMNI/Lkt reduced the number of animals showing clinical respiratory signs and the number of concomitant treatments used during the first three months after arrival at the fattening farm.

Teilen

The contents of this page are country specific and aimed specifically at prescribing veterinarians.

This product is not available in {{ preferredCountry.title }}.

You will be redirected to our global site. Click on continue to visit our global site (available in English).

Confirm that you are a veterinary professional:

This product is not available in {{ countrySelect.title }}.

You will be redirected to our global site. Click on continue to visit our global site (available in English).

  • I am a veterinarian (otherwise please contact a veterinary professional)

Select your country:

Country {{countrySelect.title}}
  • Global (available in English)
  • {{country.title}}